Vertex Pharmaceuticals Incorporated (VIE:VRTX)

Market Cap	96.54B -20.2%
Revenue (ttm)	10.22B +8.9%
Net Income	3.37B
EPS	13.05
Shares Out	n/a
PE Ratio	28.67
Forward PE	22.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	15
Open	385.65
Previous Close	389.25
Day's Range	382.75 - 388.40
52-Week Range	313.80 - 448.80
Beta	n/a
RSI	41.54
Earnings Date	May 4, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,400
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: VRTX

Financial Performance

Financial numbers in USD